L'intérêt à découvert pour Ascend Wellness Holdings donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de Ascend Wellness Holdings. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

Ascend Wellness Holdings (OTC:AAWH) Stock, Rapport sur les intérêts à découvert

Ascend Wellness Holdings Inc is a vertically integrated multi-state operator focused on adult-use or near-term adult-use cannabis states in limited licenses markets. The company's core business is the cultivation, manufacturing, and distribution of cannabis consumer packaged goods, which it sells through company-owned retail stores and third-party licensed cannabis retail stores. It generates maximum revenue from the retail product segment.

ASCEND WELLNESS HOLDNGS A by Ascend Wellness Holdings, Inc.

Ascend Wellness Holdings Inc

The U.S. Department of Justice's trial on proposed penalties against Alphabet's Google over its dominance in the online search market will not be delayed to accommodate any changes Trump administration officials wish to make, the judge overseeing the case said on Tuesday.
U.S. District Judge Amit Mehta said he would not move the trial, scheduled for April, for that purpose.
&nbsp;
"If there is going to be a re-evaluation of the remedies that are being requested, it needs to be done quickly," the judge said.
Prosecutors have asked the judge to order Google to sell its Chrome browser, share data and search results with rivals and take other measures - including possibly selling the Android mobile operating system.
Google has called the proposals staggering, and said they would harm American competitiveness.

News

Legal

"U.S. Judge In Google Search Case Says If Trump Administration Wants To Make A 'Reevaluation Of The Remedies' Then It Needs To Do So Quickly; Says April Trial In DOJ's Google Search Case Will Not Be Rescheduled For DOJ To Revise Proposals" - Reuters News

ASP Isotopes Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASPI#NASDAQ">ASPI</a>) shares are trading lower on Tuesday. The stock initially moved higher after the company announced it completed construction and started commissioning its Silicon-28 enrichment facility, but reversed course after a short seller issued a bearish report on the stock. Here&#8217;s what <a href="https://www.benzinga.com/pressreleases/24/11/g42187863/asp-isotopes-inc-completes-construction-and-starts-the-commissioning-of-silicon-28-enrichment-faci">you need to know</a>.
What Happened: Short Seller Fuzzy Panda Research issued a bearish report on ASP Isotopes on Tuesday claiming the company is using &#8220;old, disregarded laser enrichment technology to masquerade as a new, cutting-edge Uranium enrichment company.&#8221;
Fuzzy Panda claimed that it uncovered multiple stock promoters who were paid to promote ASP Isotopes. The short seller also claimed that family members of Barry Honig and John Stetson, who are currently banned from penny stocks trading, have stakes in ASP Isotopes. 
A spokesperson for ASP Isotopes told Benzinga the Fuzzy Panda report includes inaccurate claims. 
&#8220;We are aware of the report by a known activist short seller who stands to realize gains by a company's shares declining in value,&#8221; the ASP Isotopes spokesperson said. 
&#8220;The report includes inaccurate claims and innuendo in an attempt to mislead investors. As a public company traded on Nasdaq, we direct investors to our public filings made with the SEC.&#8221;
Fuzzy Panda noted in the report that Cameco looked at ASP Isotope&#8217;s technology but decided to pass on investing. The short seller also noted that the company&#8217;s recent memorandum of understanding with Bill Gates-backed <a href="https://www.benzinga.com/news/24/10/41624818/asp-isotopes-stock-is-soaring-wednesday-whats-going-on" target="_blank" rel="noreferrer noopener">TerraPower</a>&nbsp;is non-binding and did not cost TerraPower anything to enter into.
ASP Isotopes shares raced higher at the end of October after the company signed a deal with&nbsp;TerraPower&nbsp;related to&nbsp;the construction of a uranium enrichment facility capable of producing&nbsp;High Assay Low-Enriched Uranium (HALEU). ASP Isotopes said last week that it has received interest from potential customers who collectively require over $37 billion of HALEU between now and 2037.
The short seller went on to cast doubt on the company&#8217;s ability to obtain licenses and called the company&#8217;s cost estimate forecasts &#8220;delusional.&#8221; 
&#8220;Management has issued false promises and promised milestones since the beginning,&#8221; the short seller said.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/technicals/24/11/42190391/dell-93-rally-hits-q3-crossroads-whats-next-for-the-stock">Dell&#8217;s 93% Rally Hits Q3 Crossroads – What&#8217;s Next For The Stock?</a>
What Else: ASP Isotopes shares actually started the day higher after the company announced that construction of its Silicon-28 enrichment facility in South Africa was completed. The company began the commissioning phase on Tuesday and is targeting supplying commercial quantities of Silicon-28 during the first half of 2025.
Silicon-28 is an isotope that is believed to enable quantum computing and is also likely to improve the performance of next-gen AI chips. Highly enriched Silicon-28 is expected to be required by manufacturers of next-gen semiconductors, the company said. 
&#8220;To create faster, smaller next-generation semiconductors, the world is likely going to require materials that are currently not available in commercial quantities,&#8221; said Paul Mann, chairman and CEO of ASP Isotopes. 
&#8220;ASP Isotopes is currently working on many isotopically pure elements that we believe will help semiconductor companies create the chips that the world will require in the future to enable technologies such as quantum computing and artificial intelligence.&#8221;
ASP Isotopes said it already signed two supply agreements with U.S.-based customers for highly enriched Silicon-28. One of the customers is a semiconductor company and the other is an industrial gas company. ASP noted that it&#8217;s currently in discussions with multiple other potential customers and expects to sign more agreements within the next six months. 
ASPI Price Action: <a href="http://benzinga.com/quote/aspi" target="_blank" rel="noreferrer noopener">ASP Isotopes shares</a> were down 23.3% at $5.86 at the time of publication Tuesday, according to <a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Photo: Shutterstock.

Short Sellers

Movers

ASPI

What's Going On With ASP Isotopes Stock Tuesday?

Editor&#8217;s note: The headline of this story was updated to correct an error related to the reported day of the week.
On Monday, the Centers for Medicare &amp; Medicaid Services posted final payment determinations for its 2025 Clinical Laboratory Fee Schedule.
Included was a final decision related to CMS pricing for Exact Sciences Corp&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) Cologuard Plus, a second-generation test that received FDA <a target="_blank" href="https://www.benzinga.com/news/large-cap/24/10/41185292/fda-clears-exact-sciences-next-generation-colorectal-cancer-diagnostic-test" rel="noreferrer noopener">approval in October</a>.
William Blair writes that the <a target="_blank" href="https://www.cms.gov/medicare/payment/fee-schedules/clinical-laboratory-fee-schedule-clfs/annual-public-meetings" rel="noreferrer noopener">determinations</a> effectively raise reimbursement by 16% versus the current Medicare rate for the first-generation Cologuard test (to $592 for Cologuard Plus from $509 for Cologuard).
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41776963/colorectal-cancer-diagnostic-focused-exact-sciences-stock-plunges-on-weak-annual-gu" rel="noreferrer noopener">Colorectal Cancer Diagnostic Focused Exact Sciences Stock Plunges On Weak Annual Guidance, Analyst Sees Compelling Long-Term Entry Point</a>
The determination reverses the September preliminary decision but aligns with a proposal made during the public comment period.
The analyst writes that reimbursement for Cologuard Plus will now be calculated based on two components: three times the fee for methylation analysis of Septin-9 ($192 x 3) and the fee for a FIT test ($15.92).
This pricing adjustment is expected to take effect for Medicare volumes when the test officially launches in late first quarter or early second quarter of 2025. Medicare fee-for-service volumes should reflect the new pricing immediately upon launch, with Medicare Advantage following soon after.
The company is also likely to renegotiate commercial contracts for higher pricing, which may gradually roll out over the coming quarters and years.
William Blair reiterates the <a target="_blank" href="https://www.benzinga.com/quote/EXAS/analyst-ratings" rel="noreferrer noopener">Outperform rating on the stock.</a>
The analyst highlights that the update is a positive outcome for the company, as it simplifies the process of implementing a price increase compared to the more complex advanced diagnostic laboratory test (ADLT) pathway.
From a financial perspective, this decision is expected to support a moderate pricing boost starting in 2025. Based on William Blair&#8217;s estimates, this could add at least 300 basis points to Cologuard's growth rate next year, which is projected to be around 15% overall.
Exact Sciences said it will present 10 abstracts demonstrating the breadth of its Precision Oncology portfolio at the 2024 annual San Antonio Breast Cancer Symposium <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b42177702/exact-sciences-advances-breast-cancer-care-with-the-oncotype-dx-test-and-genomic-profiling-researc" rel="noreferrer noopener">scheduled next month</a>.
Price Action: EXAS stock is up 7.60% at $59.33 at last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42190381/analog-devices-q4-earnings-beats-estimates-automotive-rebound-outlook" target="_blank" rel="noreferrer noopener">Analog Devices Q4 Earnings: Beats Estimates, Automotive Rebound, Cautiously Optimistic Outlook &amp; More</a></li>
</ul>
Illustration of Phrama lab worker created with MidJourney.

Analyst Color

Equities

Health Care

Reiteration

Analyst Ratings

Trading Ideas

General

EXAS

Why Is Exact Sciences Stock Trading Higher On Tuesday? (CORRECTED)

JPMorgan Expects $5B-$15B In Outflows From Emerging Market Dedicated Bond Funds In 2025; Expects Growth To Slow In Emerging Markets To 3.4% In 2025, From 4.1% In 2024; Sees $169B Of EM Sovereign Hard Currency Gross Issuance In 2025, Marginally Less Than 2024

Government

Macro Economic Events

Politics

Economics

'Trump's Plan To Impose 25% Tariffs On Canadian And Mexican Imports Does Not Exempt Crude Oil - Sources'

<a href="https://www.reuters.com/world/middle-east/israel-security-cabinet-approves-ceasefire-deal-with-lebanon-tv-2024-11-26/" title="https://www.reuters.com/world/middle-east/israel-security-cabinet-approves-ceasefire-deal-with-lebanon-tv-2024-11-26/">https://www.reuters.com/world/middle-east/israel-security-cabinet-approves-ceasefire-deal-with-lebanon-tv-2024-11-26/</a>

iShares MSCI Israel Capped Investable Market Index Fund

'Israel Security Cabinet Approves Ceasefire Deal With Lebanon - TV' - Reuters

Whales with a lot of money to spend have taken a noticeably bullish stance on Intuitive Surgical.
Looking at options history for Intuitive Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>) we detected 11 trades.
If we consider the specifics of each trade, it is accurate to state that 54% of the investors opened trades with bullish expectations and 9% with bearish.
From the overall spotted trades, 2 are puts, for a total amount of $77,900 and 9, calls, for a total amount of $448,950.
<h3>What's The Price Target?</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $240.0 and $560.0 for Intuitive Surgical, spanning the last three months.
<h3>Volume &amp; Open Interest Development</h3>
In terms of liquidity and interest, the mean open interest for Intuitive Surgical options trades today is 157.75 with a total volume of 182.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Intuitive Surgical's big money trades within a strike price range of $240.0 to $560.0 over the last 30 days.
<h3>Intuitive Surgical Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732644997_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ISRG</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$21.3</td>
<td>$19.6</td>
<td>$19.7</td>
<td>$550.00</td>
<td>$78.8K</td>
<td align="right">575</td>
<td align="right">54</td>
</tr>
<tr>
<td>ISRG</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$65.0</td>
<td>$60.7</td>
<td>$65.0</td>
<td>$520.00</td>
<td>$65.0K</td>
<td align="right">173</td>
<td align="right">10</td>
</tr>
<tr>
<td>ISRG</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>06/20/25</td>
<td>$64.9</td>
<td>$61.4</td>
<td>$63.0</td>
<td>$520.00</td>
<td>$63.0K</td>
<td align="right">173</td>
<td align="right">20</td>
</tr>
<tr>
<td>ISRG</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$305.0</td>
<td>$300.7</td>
<td>$302.7</td>
<td>$240.00</td>
<td>$60.5K</td>
<td align="right">52</td>
<td align="right">2</td>
</tr>
<tr>
<td>ISRG</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$28.8</td>
<td>$27.6</td>
<td>$28.8</td>
<td>$560.00</td>
<td>$57.6K</td>
<td align="right">140</td>
<td align="right">20</td>
</tr>
</tbody>
</table>

<h3>About Intuitive Surgical</h3>
Intuitive Surgical develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed more than 8,600 da Vinci systems in hospitals worldwide, with more than 5,000 installations in the US and a growing number in emerging markets.
Following our analysis of the options activities associated with Intuitive Surgical, we pivot to a closer look at the company's own performance.
<h3>Present Market Standing of Intuitive Surgical</h3>
<ul>
<li>With a trading volume of 478,667, the price of ISRG is up by 0.66%, reaching $540.1.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 56 days from now.</li>
</ul>
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Intuitive Surgical, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Options

Markets

ISRG

Unpacking the Latest Options Trading Trends in Intuitive Surgical

Whales with a lot of money to spend have taken a noticeably bullish stance on Microchip Technology.
Looking at options history for Microchip Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCHP#NASDAQ">MCHP</a>) we detected 10 trades.
If we consider the specifics of each trade, it is accurate to state that 70% of the investors opened trades with bullish expectations and 20% with bearish.
From the overall spotted trades, 7 are puts, for a total amount of $647,449 and 3, calls, for a total amount of $215,668.
<h3>What's The Price Target?</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $47.5 to $87.5 for Microchip Technology during the past quarter. 
<h3>Volume &amp; Open Interest Development</h3>
In today's trading context, the average open interest for options of Microchip Technology stands at 373.38, with a total volume reaching 5,381.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Microchip Technology, situated within the strike price corridor from $47.5 to $87.5, throughout the last 30 days.
<h3>Microchip Technology Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732644993_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>MCHP</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$3.1</td>
<td>$2.95</td>
<td>$3.0</td>
<td>$70.00</td>
<td>$430.3K</td>
<td>489</td>
<td>1.4K</td>
</tr>
<tr>
<td>MCHP</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$4.9</td>
<td>$4.7</td>
<td>$4.9</td>
<td>$70.00</td>
<td>$98.0K</td>
<td>584</td>
<td>212</td>
</tr>
<tr>
<td>MCHP</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$2.3</td>
<td>$2.2</td>
<td>$2.18</td>
<td>$77.50</td>
<td>$76.7K</td>
<td>140</td>
<td>751</td>
</tr>
<tr>
<td>MCHP</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$2.05</td>
<td>$2.0</td>
<td>$2.05</td>
<td>$67.50</td>
<td>$49.6K</td>
<td>1.1K</td>
<td>435</td>
</tr>
<tr>
<td>MCHP</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$7.8</td>
<td>$7.6</td>
<td>$7.6</td>
<td>$70.00</td>
<td>$41.0K</td>
<td>298</td>
<td>314</td>
</tr>
</tbody>
</table>

<h3>About Microchip Technology</h3>
Microchip Technology became an independent company in 1989 when it was spun off from General Instrument. More than half of revenue comes from MCUs, which are used in a wide array of electronic devices from remote controls to garage door openers to power windows in autos. The company's strength lies in lower-end 8-bit MCUs that are suitable for a wider range of less technologically advanced devices, but the firm has expanded its presence in higher-end MCUs and analog chips as well.
In light of the recent options history for Microchip Technology, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Current Position of Microchip Technology</h3>
<ul>
<li>Trading volume stands at 3,162,874, with MCHP's price down by -1.88%, positioned at $68.54.</li>
<li>RSI indicators show the stock to be may be approaching oversold.</li>
<li>Earnings announcement expected in 65 days.</li>
</ul>
<h3>Professional Analyst Ratings for Microchip Technology</h3>
5 market experts have recently issued ratings for this stock, with a consensus target price of $88.4.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Susquehanna persists with their Positive rating on Microchip Technology, maintaining a target price of $90. 
&#x2A; Maintaining their stance, an analyst from Citigroup continues to hold a Buy rating for Microchip Technology, targeting a price of $82. 
&#x2A; Consistent in their evaluation, an analyst from Rosenblatt keeps a Buy rating on Microchip Technology with a target price of $90. 
&#x2A; Consistent in their evaluation, an analyst from Piper Sandler keeps a Overweight rating on Microchip Technology with a target price of $85. 
&#x2A; An analyst from Evercore ISI Group downgraded its action to Outperform with a price target of $95. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Microchip Technology, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

MCHP

Microchip Technology Unusual Options Activity

<a href="https://news.sky.com/story/apollo-in-talks-to-finance-new-york-sun-owners-550m-telegraph-bid-13261183#:~:text=The%20%24733bn%20alternative%20investments,newspaper%2C%20Sky%20News%20can%20reveal.">https://news.sky.com/story/apollo-in-talks-to-finance-new-york-sun-owners-550m-telegraph-bid-13261183#:~:text=The%20%24733bn%20alternative%20investments,newspaper%2C%20Sky%20News%20can%20reveal.</a>
&nbsp;
One of the world's largest investment groups is in talks to help finance a £550m takeover of The Daily Telegraph by the owner of The New York Sun.
Sky News has learnt that Apollo Global Management, which oversees assets worth $733bn, has been holding initial talks with Dovid Efune and his advisers in recent days about lending part of the money required for the deal.
Banking sources said on Tuesday that the discussions were preliminary in nature and might not lead to an agreement.
Other debt providers are also in talks with Mr Efune, the sources added.
The development has emerged just three days before an exclusivity period for the US-based businessman expires, although insiders say it is almost certain to be extended.
Apollo ranks among the world's biggest financial institutions and is a major player in both private equity and private credit around the globe.
In the last fortnight, a string of media reports have cast doubt on Mr Efune's ability to complete the deal, with potential lenders including Oaktree Capital Management and Hudson Bay Capital said to have withdrawn from the process.

'Apollo In Talks To Finance New York Sun-Owner's £550m Telegraph Bid; The $733B Alternative Investments Behemoth Is In Preliminary Discussions To Help Fund Dovid Efune's Takeover Of The Right-leaning Newspaper' - Sky News

Deep-pocketed investors have adopted a bullish approach towards Robinhood Markets (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in HOOD usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 35 extraordinary options activities for Robinhood Markets. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 48% leaning bullish and 37% bearish. Among these notable options, 3 are puts, totaling $329,380, and 32 are calls, amounting to $2,224,324.
<h3>Projected Price Targets</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $20.0 to $50.0 for Robinhood Markets during the past quarter. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Robinhood Markets's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Robinhood Markets's substantial trades, within a strike price spectrum from $20.0 to $50.0 over the preceding 30 days.
<h3>Robinhood Markets Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732644987_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>HOOD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$4.1</td>
<td>$3.9</td>
<td>$3.9</td>
<td>$50.00</td>
<td>$598.8K</td>
<td>2.9K</td>
<td>1.5K</td>
</tr>
<tr>
<td>HOOD</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$9.0</td>
<td>$8.9</td>
<td>$9.0</td>
<td>$37.00</td>
<td>$270.0K</td>
<td>1.2K</td>
<td>300</td>
</tr>
<tr>
<td>HOOD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>05/16/25</td>
<td>$18.25</td>
<td>$18.05</td>
<td>$18.15</td>
<td>$20.00</td>
<td>$232.3K</td>
<td>118</td>
<td>130</td>
</tr>
<tr>
<td>HOOD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/06/24</td>
<td>$1.75</td>
<td>$1.71</td>
<td>$1.75</td>
<td>$37.00</td>
<td>$117.2K</td>
<td>2.8K</td>
<td>1.2K</td>
</tr>
<tr>
<td>HOOD</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$10.95</td>
<td>$10.5</td>
<td>$10.9</td>
<td>$50.00</td>
<td>$109.0K</td>
<td>4.7K</td>
<td>137</td>
</tr>
</tbody>
</table>

<h3>About Robinhood Markets</h3>
Robinhood Markets Inc is creating a modern financial services platform. It designs its own products and services and delivers them through a single, app-based cloud platform supported by proprietary technology. Its vertically integrated platform has enabled the introduction of new products and services such as cryptocurrency trading, dividend reinvestment, fractional shares, recurring investments, and IPO Access. It earns transaction-based revenues from routing user orders for options, equities, and cryptocurrencies to market makers when a routed order is executed.
After a thorough review of the options trading surrounding Robinhood Markets, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Robinhood Markets's Current Market Status</h3>
<ul>
<li>With a trading volume of 8,734,368, the price of HOOD is down by -1.95%, reaching $37.11.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 77 days from now.</li>
</ul>
<h3>Expert Opinions on Robinhood Markets</h3>
Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $33.6.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Goldman Sachs persists with their Neutral rating on Robinhood Markets, maintaining a target price of $25. 
&#x2A; An analyst from Needham upgraded its action to Buy with a price target of $40. 
&#x2A; Maintaining their stance, an analyst from Goldman Sachs continues to hold a Neutral rating for Robinhood Markets, targeting a price of $22. 
&#x2A; An analyst from Barclays persists with their Equal-Weight rating on Robinhood Markets, maintaining a target price of $26. 
&#x2A; An analyst from Morgan Stanley has elevated its stance to Overweight, setting a new price target at $55. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Robinhood Markets with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

HOOD

Spotlight on Robinhood Markets: Analyzing the Surge in Options Activity

Retirement brings exciting possibilities but also requires careful financial planning to ensure long-term stability. In a <a href="https://omny.fm/shows/suze-ormans-women-and-money/ask-kt-suze-anything-highlights-from-create-the-li">recent Women &amp; Money podcast episode</a>, financial expert <a href="https://www.benzinga.com/personal-finance/24/11/42094171/new-car-or-old-reliable-suze-ormans-surprising-advice-on-listeners-20-year-old-car">Suze Orman</a> responded to a listener named Linda, who asked whether retirees should keep one year or five years' cash in an emergency fund. Orman's advice offered insights into navigating market fluctuations during retirement.&nbsp;
Don't Miss:
<ul>
<li><a href="https://www.benzinga.com/money/cd-valet-growth">CD Popularity Soars: Over 50 Million Americans Embrace Safe Savings with 5–10% Annual Growth</a></li>
<li>Can you guess how many retire with a $5,000,000 nest egg? <a href="https://www.benzinga.com/money/5mil-nest-egg-adv">The percentage may shock you</a>.</li>
<li>The number of ‘401(k)' Millionaires is up 43% from last year —<a href="https://www.benzinga.com/money/401k-millionaires"> Here are three ways to join the club.</a></li>
</ul>
According to Orman, most retirees depend on their retirement accounts, such as Roth or traditional IRAs, to fund their monthly living expenses. These accounts often hold investments in stocks, bonds or mutual funds. While these assets grow over time, their value fluctuates with the market.&nbsp;
Orman says the problem arises when retirees need to withdraw money from their accounts during a market crash. Selling stocks or bonds during a market downturn can cut into retirement savings, potentially jeopardizing future <a href="https://www.benzinga.com/personal-finance/24/09/40764819/think-youre-financially-secure-heres-how-much-people-say-it-takes-to-feel-secure-and-what-you-re">financial security</a>.&nbsp;
To address this risk, Orman recommends that retirees keep a cash reserve with three to five years of living expenses. "If you really wanna be on the safe side, it's five years," she said.&nbsp;
See Also: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> you can become an investor for $0.80 per share today.</a>
This cash reserve acts as a safety net, allowing retirees to withdraw the funds they need rather than selling and withdrawing from their investment accounts during a market slump.&nbsp;
Orman explains that keeping three to five years&#8217; worth of expenses is important because that's how long it often takes the markets to recover from significant downturns. Having enough cash for that time minimizes the need to sell at a loss, ensuring retirees can leave their investments alone long enough to regain their value.&nbsp;
It usually takes the markets longer to recover during a recession. According to Invesco, the average decline during the "more mild" recessions in the '80s and '90s was around 20% and the stock market recovered from these within one to two years.&nbsp;
The more extreme recessions, like the 2008 financial crisis, extend that recovery time. 5 paisa, an online investing and trading platform, states it wasn't until 2013 that the market recovered to its precrisis levels.&nbsp;
Trending: <a href="https://www.benzinga.com/money/100k-cd">$100K Sitting In A CD Account, Should I Move Money Into The Stock Market?</a>
If you're <a href="https://www.benzinga.com/personal-finance/24/10/41602038/new-report-reveals-62-of-u-s-retirees-leave-the-workforce-sooner-than-expected-and-people-are-no">nearing retirement</a> and don't yet have a sufficient cash reserve, Orman recommends creating one strategically. She says to evaluate your investments and consider selling stocks or assets that aren't performing well or that you don't believe will yield strong future returns. Another option she proposes is taking small amounts from well-performing investments to gradually build your reserve.&nbsp;
For those needing access to their money immediately, Ameriprise Financial recommends keeping cash reserves in a high-yield savings or deposit account, cash management account or sweep account. Alternatively, if you can wait one to three months to access those cash reserves – for instance, if you have a couple months of cash to cover expenses in your checking account – they say to consider keeping the funds in money market funds or investment certificates.&nbsp;
For retirees like Linda, maintaining three to five years of cash reserves is a proactive step toward financial security. This strategy protects against the unpredictability of market downturns and allows investments to recover without being prematurely liquidated.
Read Next:
<ul>
<li>Many are using this retirement income calculator to check if they&#8217;re on pace —<a href="https://www.benzinga.com/money/how-do-i-calculate-my-retirement-income-adv"> here&#8217;s a breakdown on how on what&#8217;s behind this formula.</a></li>
<li>Studies show 50% of consumers think Financial Advisors cost much more than they do —<a href="https://www.benzinga.com/money/money-pickle"> to debunk this, this company provides matching for free and a complimentary first call with the matched advisor.</a></li>
</ul>

Personal Finance

Suze Orman Says To Have At Least 3 To 5 Years Of Cash Available When Retired: Here's Why

On Tuesday, Embecta Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EMBC#NASDAQ">EMBC</a>) posted&nbsp;the fourth-quarter adjusted EPS of 45 cents, beating the consensus of 36 cents and down from 59 cents reported a year ago.
The company reported quarterly sales of $286.1 million, up 1.5% year over year, beating the <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g42184816/embecta-corp-reports-fiscal-2024-fourth-quarter-and-full-year-financial-results-provides-initial-f" rel="noreferrer noopener">consensus of $277 million</a>.
&#8220;We are pleased to report a strong fourth quarter and end to our fiscal year, as we once again delivered results that exceeded our expectations across key financial metrics&#8230;Additionally, the recent launch of our small-pack GLP-1 needles in Germany has gone well, and we are evaluating expanding into other markets,&#8221; said Devdatt (Dev) Kurdikar, Chief Executive Officer of Embecta.
The Becton, Dickinson and Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDX#NYSE">BDX</a>) spin-off announced that it decided to discontinue its insulin patch pump program and plans to initiate a restructuring plan.
In July, Embecta, a manufacturer of disposable&nbsp;insulin pen needles&nbsp;and syringes, said it is considering a potential sale following a significant drop in its share price since being spun off from health tech <a target="_blank" href="https://www.benzinga.com/m-a/24/07/39916116/insulin-device-maker-embecta-weighs-sale-after-70-share-decline-following-becton-dickinson-spin-off" rel="noreferrer noopener">giant&nbsp;Becton, Dickinson</a>.
&#8220;We intend to concentrate our resources on our core business and to prioritize our free cash flow towards paying down debt, which we expect will give us the financial flexibility needed for future investments,&#8221; Kurdikar said.
Embecta expects between $25 million and $30 million in pre-tax, cash charges for planned workforce reductions and other associated costs from the discontinuation of its patch pump program.
In total, Embecta expects between $35 million and $45 million in pre-tax charges in 2025 related to its restructuring plan. It anticipates completing the restructuring in the first half of 2025. Embecta projects annual cost savings of $60 million to $65 million from this restructuring.
Given the organizational restructuring plan, the company has postponed its Analyst &amp; Investor Day to Spring 2025.
Guidance: Embecta says that for the fiscal year 2025, excluding the Patch Pump program, revenues are expected to be $1.093 billion—$1.11 billion compared to a consensus of $1.12 billion, with an adjusted EPS of $2.70—$2.90 versus the consensus of $2.27.
Price Action: EMBC stock is up 33.5% at $19.23 at last check Tuesday.
Image via Unsplash
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42195803/why-is-exact-sciences-stock-trading-higher-on-monday" target="_blank" rel="noreferrer noopener">Why Is Exact Sciences Stock Trading Higher On Monday?</a></li>
</ul>

Earnings

Guidance

EMBC

Becton Dickinson Spinoff Embecta Stops Insulin Patch Pump Program, Plans Restructuring, Stock Jumps

<a href="https://ppubs.uspto.gov/pubwebapp/external.html?q=(12152936).pn">https://ppubs.uspto.gov/pubwebapp/external.html?q=(12152936).pn</a>
<figure class="image"><img src="https://pbs.twimg.com/media/GdU1yQkWQAAh4uq?format=jpg&amp;name=900x900" alt="Image" /></figure>

Quantum-Si Granted US Patent #12152936 For "INTEGRATED CIRCUIT WITH SEQUENTIALLY-COUPLED CHARGE STORAGE AND ASSOCIATED TECHNIQUES"

Anthony Scaramucci opined on President-elect Donald Trump&#8216;s successful election bid, analyzed the results and their implications <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42109267/bitcoin-hits-new-all-time-high-above-98000-as-spot-etfs-crack-100-billion-net-asset-value-milestone">for crypto policy</a>.
What Happened: In a recent <a href="https://www.youtube.com/watch?v=C9Yh-2jNTdI">episode</a> of The Scoop podcast with Frank Chaparro, the former White House Communications Director pointed to Vice President Kamala Harris's loss as a consequence of economic concerns and unreliable polling, calling Trump's narrow win "the greatest political comeback in U.S. history."
On the topic of crypto, Scaramucci asserted that the Democrats&#8217; anti-crypto stance hurt their political standing, stating, "You won no electoral votes, you won no States, you won no seats in the senate or the house being anti-crypto."
He suggested that <a href="https://www.benzinga.com/news/legal/24/11/41996491/18-republican-states-sue-bidens-sec-over-harsh-crypto-crackdown">regulatory roadblocks</a> under the Democrats suppressed the crypto market, adding, "Where you are now in price is where we should have been three years ago."
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42024635/scaramucci-trumps-crypto-support-could-push-bitcoin-to-150k">Scaramucci: Trump&#8217;s Crypto Support Could Push Bitcoin To $150K</a>
Why It Matters: Scaramucci predicts the incoming Trump administration will prioritize loyalty over expertise, creating a potentially disruptive cabinet. 
He highlighted concerns over controversial appointments, <a href="https://www.benzinga.com/politics/24/11/42170037/elon-musk-said-matt-gaetz-would-be-hammer-of-justice-as-attorney-general-former-congressman-now-unemployed-sells-cameos-for-500">including Matt Gaetz</a>, but expressed optimism about crypto-related appointments like Brian Brooks as <a href="https://www.benzinga.com/trading-ideas/movers/24/11/42053981/trump-sec-pick-speculation-sends-this-altcoin-soaring-past-bitcoin-and-ethereum-in-daily-gains">a possible SEC chair</a>.
The crypto <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42122348/trumps-planned-crypto-council-may-oversee-bitcoin-reserve-report">surge following Trump's re-election</a>, Scaramucci noted, represents the market correcting itself after years of regulatory suppression. 
However, he also warned of a potential &#8220;rug pull&#8221; scenario, advising caution despite his overall optimism.
Scaramucci briefly commented on <a href="https://www.benzinga.com/startups/24/11/42069236/trump-tasked-elon-musk-to-oversee-government-efficiency-heres-how-musk-has-streamlined-costs-at-his-own-companies">Trump's relationship</a> with Elon Musk, describing it as "unsustainable" due to Trump's resistance to anyone becoming "richer or more famous" than him.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/social-media/24/11/42154487/robert-kiyosaki-trump-will-make-america-richer-again-by-being-the-first-bitcoin-president">Robert Kiyosaki: &#8216;Trump Will Make America Richer Again By Being The First Bitcoin President&#8217;</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Anthony Scaramucci: Trump Win Is 'The Greatest Political Comeback In US History,' Crypto Surge Following It Was 3 Years Overdue

<a href="https://www.cbsnews.com/news/us-air-force-drone-sightings-uk-military-bases-unexplained-ongoing/" title="https://www.cbsnews.com/news/us-air-force-drone-sightings-uk-military-bases-unexplained-ongoing/">https://www.cbsnews.com/news/us-air-force-drone-sightings-uk-military-bases-unexplained-ongoing/</a>

'U.S. Air Force Says Unexplained Drone Sightings Near U.K. Military Bases Ongoing' - CBS

Bird flu has been detected in a batch of raw milk sold in California and a voluntary recall of the milk has been issued at the request of the state's <a href="https://www.benzinga.com/general/health-care/24/11/42087908/mutated-bird-flu-case-in-california-puts-humans-at-increased-risk-so-which-companies-are-developing-vaccines">department of public health.&nbsp;</a>
The Details: The virus was found during testing of a batch of whole raw milk from Raw Farm in Fresno county. The company has issued a voluntary recall of the batch, which has a &#8220;best by date&#8221; of Nov. 27. 
"Out of an abundance of caution, and due to the ongoing spread of bird flu in dairy cows, poultry, and sporadic human cases, consumers should not consume any of the affected raw milk," the California Department of Public Health said in <a href="https://www.cdph.ca.gov/Programs/OPA/Pages/NR24-039.aspx">a Sunday statement.&nbsp;</a>
Read More: <a href="https://www.benzinga.com/24/11/42194570/starbucks-employee-systems-down-after-software-provider-suffers-ransomware-attack">Starbucks&#8217; Employee Systems Down After Software Provider Suffers Ransomware Attack</a>
California reported 29 confirmed human cases of bird flu since early October, with 28 of the cases resulting from direct contact with infected dairy cows. No person-to-person spread of bird flu has been detected in California or the U.S., according to the state's public health department.&nbsp;
Vaccine Efforts: As concern about the possible spread of bird flu grows, the U.S. government is increasing its efforts to develop a stockpile of vaccines for the disease.&nbsp;
Moderna (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) received a $176 million government contract in July to advance development of its bird flu vaccine, leveraging the same mRNA technology used in the company's COVID-19 vaccine.&nbsp;&nbsp;
In October, the Department of Health and Human Services granted GSK plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>), Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) and Australian firm CSL Limited $72 million to <a href="https://www.benzinga.com/general/biotech/24/10/41188886/gsk-sanofi-and-csl-secure-us-government-fund-to-boost-bird-flu-vaccine-production-report">more than double</a> the U.S. supply of bird flu vaccines.&nbsp;
According to the CDC, 55 total cases have been reported in the 2024 bird flu outbreak in the U.S. The CDC said that it is monitoring <a href="https://www.cdc.gov/bird-flu/situation-summary/index.html">the bird flu situation </a>carefully and working with states to monitor people with animal exposures, though the current public health risk is low.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/movers/24/11/41949068/bitcoin-could-reach-1-million-by-2037-economist-says-buy-of-a-lifetime-opportunity">Bitcoin Could Reach $1 Million By 2037, Economist Says: &#8216;Buy Of A Lifetime&#8217; Opportunity</a></li>
</ul>
Photo: Pexels

Biotech

MRNA

Bird Flu Found In Raw Milk Leads To Recall In California

Wolfe Research analyst Timna Tanners downgrades Summit Materials (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SUM#NYSE">SUM</a>) from Outperform to Peer Perform.

Downgrades

Wolfe Research Downgrades Summit Materials to Peer Perform

Wolfe Research analyst Scott Group initiates coverage on Aurora Innovation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUR#NASDAQ">AUR</a>) with a Peer Perform rating.

Initiation

Wolfe Research Initiates Coverage On Aurora Innovation with Peer Perform Rating

WIIM

ICAD

iCAD shares are trading higher after the company announced it will present its next-generation AI solutions and a second-read AI partnership with Cascaid Health at the RSNA 2024 Annual Meeting.

Wolfe Research analyst Nigel Coe initiates coverage on Pentair (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PNR#NYSE">PNR</a>) with a Outperform rating and announces Price Target of $125.

Price Target

Wolfe Research Initiates Coverage On Pentair with Outperform Rating, Announces Price Target of $125

Polls show support for marijuana legalization in red states

I Still Like Ascend Wellness Despite The Management Turnover

Marijuana rescheduling hearing reportedly delayed

Ascend Wellness Holdings GAAP EPS of -$0.13, revenue of $141.6M

Weed stocks spike after report on Trump support for marijuana reforms

Ascend Wellness Holdings, Inc (AAWH) Q3 2024 Earnings Call Transcript

In a report released today, Neal Gilmer from Haywood maintained a Buy rating on Ascend Wellness Holdings LLC (AAWH – Research Report). The company'...

Ascend Wellness Holdings LLC (AAWH) Receives a Buy from Haywood

Cannabis stocks gain as Trump picks pro-marijuana Congressman Gaetz for AG post

In this week's "Rising High," The Fly's recurring series focused on cannabis and psychedelic stock news, The Fly looks back on earnings, a Phase 3 ...

Rising High: Cannabis firms report quarterly earnings

Cause For Concern In Cannabis With A Few Rays Of Light

AAWH

ACRHF

AGFY

ATAI

AYRWF

AYWWF

CANN

CBSTF

CMPS

CNBS

CNTMF

CRLBF

CRON

CURLF

CVSI

CYBN

ENVB

GHBWF

GLASF

GRUSF

GRWG

GTBIF

IIPR

IMCC

JUSHF

MEDIF

MSOS

NLCP

PLNH

RLMD

SHFS

TCNNF

TLRY

TSNDF

VREOF

VRNOF

YOLO

Small Cap

Press Releases

Ascend Wellness Expands Access to Non-Medical Cannabis Customers in Ohio

Contracts

Curio Wellness and Ascend Wellness Announce Manufacturing and Distribution Partnership

Penny Stocks

Ascend Wellness Expands Access to Non-Medical Cannabis At Its Fifth Retail Location in Ohio

Presenting on the Emerging Growth Conference 74 Day 1 on August 21 Register Now

Presenting on the Emerging Growth Conference 74 Day 2 on August 22 Register Now

Ascend Wellness Holdings Announces Leadership Updates

Ascend Continues to Grow Retail Footprint with Fifth Dispensary in Pennsylvania and its 39th Nationwide

AWH to Hold Third Quarter 2024 Earnings Conference Call on Tuesday November 12, 2024

Ascend Wellness Holdings Introduces "Effin'"--A New Edibles Brand Delivering Targeted Effects

Comments

Ascend Wellness Holdings

Intérêt court

Ascend Wellness Holdings (OTC:AAWH) Stock, Rapport sur les intérêts à découvert

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL